Terms: = Ovarian cancer AND HIF1A, Q16665, 3091, ENSG00000100644, MOP1, HIF1-ALPHA, PASD8, HIF-1alpha AND Diagnosis
12 results:
1. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
2. Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS.
Chao A; Huang HJ; Lin CY; Lee CH; Lin CH; Chao AS; Lai CH; Chang TC; Wu KY; Wu RC
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37655726
[TBL] [Abstract] [Full Text] [Related]
3. Development and Validation of a Hypoxia-related Prognostic Model for ovarian cancer.
Xie L; Pan M; Zhang Z; Jiang X; Chen Y; Liu G; Chen Y; Zeng Y; Guan J; Lu R; Zeng L
Recent Pat Anticancer Drug Discov; 2022; 18(2):161-173. PubMed ID: 35747984
[TBL] [Abstract] [Full Text] [Related]
4. Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.
Wang H; Jia D; Yuan D; Yin X; Yuan F; Wang F; Shi W; Li H; Zhu LM; Fan Q
J Nanobiotechnology; 2021 May; 19(1):138. PubMed ID: 33985511
[TBL] [Abstract] [Full Text] [Related]
5. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
Su S; Dou H; Wang Z; Zhang Q
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):224-233. PubMed ID: 32905663
[TBL] [Abstract] [Full Text] [Related]
6. A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells.
Chen C; Sun J; Chen S; Liu Y; Zhu S; Wang Z; Chang S
Int J Nanomedicine; 2019; 14():753-769. PubMed ID: 30718954
[TBL] [Abstract] [Full Text] [Related]
7. Association of the hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms with prognosis in ovarian clear cell carcinoma.
Suzuki H; Yano M; Miyazawa M; Miyazawa M; Ogane N; Hasegawa K; Tsuda H; Yoshida M; Okagaki R; Ishihara O; Yasuda M
J Ovarian Res; 2019 Jan; 12(1):7. PubMed ID: 30678691
[TBL] [Abstract] [Full Text] [Related]
8. Investigation of hypoxia networks in ovarian cancer via bioinformatics analysis.
Zhang K; Kong X; Feng G; Xiang W; Chen L; Yang F; Cao C; Ding Y; Chen H; Chu M; Wang P; Zhang B
J Ovarian Res; 2018 Feb; 11(1):16. PubMed ID: 29482638
[TBL] [Abstract] [Full Text] [Related]
9. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer.
Shen W; Li HL; Liu L; Cheng JX
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2596-2603. PubMed ID: 28678326
[TBL] [Abstract] [Full Text] [Related]
10. Hypoxia is important in F‑18 FDG accumulation in thecoma‑fibroma tumors on F‑18 FDG PET/CT scans.
Seino H; Ono S; Miura H; Morohashi S; Wu Y; Tsushima F; Takai Y; Kijima H
Mol Med Rep; 2016 May; 13(5):3821-7. PubMed ID: 27035330
[TBL] [Abstract] [Full Text] [Related]
11. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract] [Full Text] [Related]
12. The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia.
Zhu P; Ning Y; Yao L; Chen M; Xu C
J Exp Clin Cancer Res; 2010 Sep; 29(1):124. PubMed ID: 20831794
[TBL] [Abstract] [Full Text] [Related]
